Goodson Drug Co., Inc. v. U.S. Attorney General
This text of Goodson Drug Co., Inc. v. U.S. Attorney General (Goodson Drug Co., Inc. v. U.S. Attorney General) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
USCA11 Case: 25-13954 Document: 23-1 Date Filed: 04/07/2026 Page: 1 of 3
NOT FOR PUBLICATION
In the United States Court of Appeals For the Eleventh Circuit ____________________ No. 25-13954 Non-Argument Calendar ____________________
GOODSON DRUG CO., INC., J. LEE GOODSON, Plaintiffs-Appellants, versus
U.S. ATTORNEY GENERAL, U.S. DEPUTY ATTORNEY GENERAL, ADMINISTRATOR OF THE UNITED STATES DEA, THE UNITED STATES DRUG ENFORCEMENT ADMINISTRATION, Defendants-Appellees. ____________________ Appeal from the United States District Court for the Northern District of Georgia D.C. Docket No. 2:25-cv-00257-RWS ____________________
Before JILL PRYOR, BRANCH, and GRANT, Circuit Judges. USCA11 Case: 25-13954 Document: 23-1 Date Filed: 04/07/2026 Page: 2 of 3
2 Opinion of the Court 25-13954
PER CURIAM: To dispense controlled substances, a pharmacy must maintain a registration with the United States Drug Enforcement Agency. See 21 U.S.C. §§ 822(a), 823(b). Last year, the agency ordered Goodson Drug Company to show cause as to why its registration should not be revoked on the grounds that its practices in dispensing opioids and other drugs raised “red flags” for patient abuse and diversion. See id. § 824(c). Goodson filed suit in federal court. Among other claims (not relevant to this appeal), Goodson challenges the agency’s adjudicative process as unconstitutional. Specifically, it contends that the statutory for-cause tenure protections enjoyed by the agency’s administrative law judges usurp the President’s removal power under Article II. See 5 U.S.C. § 7521(a). The district court declined to issue a preliminary injunction enjoining the agency’s show cause proceedings. Because Goodson’s theory is squarely foreclosed by our precedent, we affirm. In Walmart, Inc. v. Chief Administrative Law Judge, 144 F.4th 1315 (11th Cir. 2025), we rejected a nearly identical challenge to § 7521(a)’s for-cause removal protections with respect to the administrative law judges housed under the Department of Justice’s Office of the Chief Administrative Hearing Officer—a component of the Executive Office for Immigration Review. Id. at 1319, 1345–48. Goodson does not so much as try to distinguish that case from this one, arguing instead that the panel in Walmart got it wrong. But under our prior-panel-precedent rule, that case “is USCA11 Case: 25-13954 Document: 23-1 Date Filed: 04/07/2026 Page: 3 of 3
25-13954 Opinion of the Court 3
binding on all subsequent panels unless and until it is overruled or undermined to the point of abrogation by the Supreme Court or by this court sitting en banc.”1 United States v. Archer, 531 F.3d 1347, 1352 (11th Cir. 2008).
* * *
Unable to establish “a substantial likelihood of success on the merits,” Goodson is not entitled to a preliminary injunction against the agency’s show cause order. 2 See Palmer v. Braun, 287 F.3d 1325, 1329, 1334–35 (11th Cir. 2002). We AFFIRM.
1 Goodson contends that our holding in Walmart contradicts the Supreme
Court’s earlier decision in Axon Enterprise, Inc. v. Federal Trade Commission, 598 U.S. 175 (2023). We do not see how. Axon Enterprise held that district courts have jurisdiction to decide constitutional claims challenging the structure of an agency’s adjudicative process. Id. at 180. Rather than “resolve those challenges,” the Supreme Court only addressed “where they may be heard.” Id. Here, there is no question that the district court properly exercised jurisdiction over Goodson’s constitutional claim. Axon Enterprise does not speak to the merits of that claim. In any event, our prior-panel-precedent rule contemplates no carveout “for overlooked or misinterpreted Supreme Court precedent.” United States v. Fritts, 841 F.3d 937, 942 (11th Cir. 2016). 2 Goodson forfeited its nondelegation and Article III theories by failing to raise
them below. See Green v. Graham, 906 F.3d 955, 963 (11th Cir. 2018).
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
Goodson Drug Co., Inc. v. U.S. Attorney General, Counsel Stack Legal Research, https://law.counselstack.com/opinion/goodson-drug-co-inc-v-us-attorney-general-ca11-2026.